SaNOtize breakthrough treatment 99% effective against COVID-19
pharmafile | February 9, 2022 | News story | Research and Development |
SaNOtize and Glenmark Pharmaceuticals Limited have announced successful results of their Phase III clinical trials, as well as the approval from India’s drug regulator for the treatment of adult patients with COVID-19 who have a risk of progression of the disease.
This study confirmed that SaNOtize’s Nitric Oxide Nasal Spray (NONS) represents a safe and effective aniviral treatment that shortens the course of COVID-19, and could prevent the transmission of COVID-19.
In a randomised, double-blind, placebo-controlled study at 20 clinical sites across India that evaluated 306 patients, NONS reduced the SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 houts of treatment, and by over 99% in 48 hours as compared to saline control.
In the high-risk group, treatment also demonstrated a statistically significant greater proportion of patients who achieved a combination of clinical and virological cure, based on WHO Progression Scale.
The SaNOtize treatment is designed to kill the virus in the upper airways, preventing it from incubating and spreading into the lungs. It is based on nitric oxide (NO), a natural nanomolecule produced by the human body, with proven anti-microbial properties shown to have a direct effect on SARS-CoV-2.
“These results definitively substantiate the safety and efficacy of NONS in the fight against COVID-19,” said Dr Gilly Regev, SaNOtize Co-Founder and CEO. “We are thrilled to be able to provide COVID patients with an affordable product that has been shown to deliver a faster cure. And with the proven safety profile of NONS, we look forward to this becoming the first line of treatment and potentially defence for COVID infection worldwide.”
Lina Adams
